Previous Article | Next Article 
Journal of Virology, February 2000, p. 1258-1266, Vol. 74, No. 3
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Toward a More Accurate Quantitation of the Activity
of Recombinant Retroviruses: Alternatives to Titer and Multiplicity
of Infection
Stylianos
Andreadis,
Thomas
Lavery,
Howard E.
Davis,
Joseph
M.
Le Doux,
Martin L.
Yarmush, and
Jeffrey R.
Morgan*
Center for Engineering in Medicine and
Surgical Services, Massachusetts General Hospital, Harvard Medical
School, and Shriners Hospital for Children, Boston, Massachusetts 02114
Received 5 August 1999/Accepted 2 November 1999
 |
ABSTRACT |
In this paper, we present a mathematical model with experimental
support of how several key parameters govern the adsorption of active
retrovirus particles onto the surface of adherent cells. These
parameters, including time of adsorption, volume of virus, and the
number, size, and type of target cells, as well as the intrinsic
properties of the virus, diffusion coefficient, and half-life
(t1/2), have been incorporated into a
mathematical expression that describes the rate at which active virus
particles adsorb to the cell surface. From this expression, we have
obtained estimates of Cvo, the starting
concentration of active retrovirus particles. In contrast to titer,
Cvo is independent of the specific conditions of the assay. The relatively slow diffusion (D = 2 × 10
8 cm2/s) and rapid decay
(t1/2 = 6 to 7 h) of retrovirus
particles explain why Cvo values are
significantly higher than titer values. Values of
Cvo also indicate that the number of defective
particles in a retrovirus stock is much lower than previously thought,
which has implications especially for the use of retroviruses for in vivo gene therapy. With this expression, we have also computed AVC
(active viruses/cell), the number of active retrovirus particles that
would adsorb per cell during a given adsorption time. In contrast to
multiplicity of infection, which is based on titer and is subject to
the same inaccuracies, AVC is based on the physicochemical parameters
of the transduction assay and so is a more reliable alternative.
 |
INTRODUCTION |
Recombinant retroviruses are
promising vehicles for the transfer of genes into mammalian cells for
the purpose of gene therapy and have been tested clinically for the
treatment of a variety of diseases, including cancer and AIDS
(8). As the number of clinical studies increases, the
quantitation of stocks of retrovirus and comparisons between different
laboratories and clinical trials will become increasingly important.
This task can be facilitated by a quantitative understanding of the
steps of retrovirus-mediated gene transfer. These analyses can provide
insight into the effects that key physicochemical factors have on
transduction and suggest new strategies to improve the efficiency of
retrovirus-mediated gene transfer.
Stocks of recombinant retroviruses are typically quantitated by
measuring titer, the number of gene transfer events per unit volume of
retrovirus solution. To determine titer, the virus stock is first
diluted a few 1,000-fold and then used to transduce target cells. The
titer, expressed as the number of CFU/milliliter, is the number of
colonies of transduced cells multiplied by the dilution factor and
divided by the volume of retrovirus applied to the target cells. The
visualization and quantitation of transduced cells are achieved by the
use of retrovirus vectors that carry reporter genes, such as the
lacZ gene, or antibiotic resistance genes, such as the
neo gene.
Although titer is a conventional measure of retrovirus bioactivity, it
suffers from certain problems and inconsistencies. The number of gene
transfer events depends on the specific conditions of the assay, and
standardized conditions have not been established. Numerous factors can
influence titer, including the time of exposure of cells to the virus,
the number and type of target cells, the volume of the virus-containing
medium, and the half-life (t1/2) of retrovirus
particles. Thus, titer reflects the number of gene transfer events
under a highly specific set of conditions. With these caveats, it is
clear that titer is not an absolute measure of the concentration of
active retrovirus particles. Compounding these problems is the fact
that values for titer are incorporated into the calculation of the
multiplicity of infection (MOI), the expected number of gene transfer
events per cell. Even though MOI has been shown to be an unreliable and
inaccurate predictor of the transduction process (15), it is
still commonly used to predict the extent to which a cell population is
genetically modified. Clearly, a more accurate and reliable
quantitative measure of retrovirus activity is needed to help
standardize stocks of virus as well as predict the potency with which
these virus stocks can deliver genes to a target cell population.
Here, we present experimental data and mathematical analyses of a
critical step in retrovirus-mediated gene transfer, the diffusion and
adsorption of virus particles on target cells. We show that the
adsorption of these relatively large virus particles is diffusion
limited. Moreover, transduction is also limited by the fact that virus
particles lose bioactivity with time (t1/2 = 6 to 7 h). Thus, only a small fraction (~10%) of the total
number of active virus particles in a stock are able to diffuse,
adsorb, and successfully transduce a target cell before the particles lose their biological activity. These results demonstrate that, contrary to widespread perception, many of the particles in a stock of
recombinant retroviruses are initially active particles. Stocks do not
contain large numbers of defective particles. Rather, the combined
limitations of slow diffusion and virus decay limit the ability of
particles to successfully infect a cell. We have incorporated these
physicochemical parameters of diffusivity and half-life, along with the
number and size of the target cells and the time of adsorption, into a
mathematical model that can be used to calculate the initial
concentration of active retrovirus particles in a starting stock
(Cvo). Since Cvo is
independent of the conditions of the transduction assay, it is more
reliable and may aid in the standardized comparisons of the potency of stocks of virus. Moreover, with this model, we present an alternative to MOI that is more reliable at predicting the expected number of gene
transfer events in a population of adherent cells.
 |
MATERIALS AND METHODS |
Cell culture.
Human fibroblasts (HuFb) were isolated from
newborn human foreskins. Briefly, the tissue was trimmed to remove the
fat and muscle layers underlying the dermis and then repeatedly rinsed in sterile phosphate-buffered saline (PBS). The tissue was subsequently cut into small pieces (0.2 × 0.2 cm2) and placed on
the tissue culture plate, with the dermal side contacting the tissue
culture plate. After allowing the skin pieces to dry to the tissue
culture plate for approximately 45 min, 10 ml of Dulbecco's modified
Eagle's medium (Gibco BRL, Gaithersburg, Md.) containing 20% fetal
bovine serum (HyClone Laboratories, Inc., Logan, Utah), 100 U of
penicillin, and 100 µg of streptomycin (Gibco BRL) per ml was added
to the tissue culture plate and placed in an incubator at 37°C with
10% CO2. The medium was changed every 3 to 4 days. Seven
to 10 days later, fibroblasts migrated out from the dermis onto the
surface of the tissue culture plate. Thereafter, the cells were passed
every week when they reached confluence.
NIH 3T3 cells and lacZ virus-producing cell lines were
cultured in Dulbecco's modified Eagle's medium (Gibco BRL) with 10% bovine calf serum (HyClone Laboratories, Inc.), 100 U of penicillin, and 100 µg of streptomycin (Gibco BRL) per ml at 37°C with 10% CO2. lacZ virus-containing medium was harvested
from confluent cultures of an amphotropic packaging cell line (
CRIP)
(15). Fresh medium (10 ml in a 10-cm tissue culture dish)
was added to the cells 24 h before the virus was harvested. The
lacZ virus-containing medium was filtered through
0.45-µm-pore-size filters (Gelman Sciences, Ann Arbor, Mich.),
aliquoted, and stored at
80°C until use.
Transduction assay.
Tenfold serial dilutions of the
lacZ virus stocks were made in cell culture medium.
Polybrene was added at a concentration of 8 µg/ml and 2 ml of virus
was added to the target cells plated in six-well plates (Costar Corp.,
Cambridge, Mass.) the previous day. At the end of exposure of cells to
the virus (time as indicated in each experiment), the virus-containing
medium was removed, fresh medium was added, and the cells were allowed
to grow for 48 h. Subsequently, the cells were fixed and stained
for
-galactosidase activity with
5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-Gal).
Briefly, cells were washed with PBS and fixed in PBS containing 0.5%
glutaraldehyde for 10 min at room temperature. Plates were washed with
PBS containing 1 mM MgCl2 and stained for lacZ
activity by incubation in a solution containing PBS, 1 mM
MgCl2, 3.3 mM K3Fe(CN)6, 3.3 mM
K4Fe(CN)6 · 3H2O, and 1 mg of X-Gal per ml overnight at 37°C. The reaction mixture was removed, and the cells were washed with PBS and air dried. Colonies of lacZ+ cells were counted with the aid of a
dissecting microscope.
Measurements of target cell surface area.
The average size
of the target cells (NIH 3T3 and HuFb) was determined experimentally by
fluorescence microscopy. Cells were plated in six-well plates, and the
next day they were stained with 10 µmol of the cytoplasmic dye
CellTracker Orange CMTMR
(5-(and-6)-(((4-chloromethyl)benzoyl)amino)tetramethylrhodamine) for 60 min at 37°C (Molecular Probes, Eugene, Oreg.). The CellTracker probe
allows labeling of viable cells for at least 24 h after loading
and often through several cell divisions. The cells were viewed with a
fluorescence microscope (Nikon Diaphot). Forty areas were randomly
selected in six identical wells for image analysis. In each area,
several cells were selected at random and the surface area was
determined by delineating the perimeter of each cell with the computer
software Metamorph (Universal Imaging Corp., West Chester, Pa.). When
cells were close to each other so that their borders could not be
easily distinguished, they were excluded from the analysis. More than
100 cells were used and the average surface area was calculated.
Quantitation of retrovirus adsorption by an ELISA for p30 capsid
protein.
Target cells (NIH 3T3 and HuFb) were grown to confluence
in six-well plates, and 1 ml of undiluted virus was added at
t = 0. At various times, the virus was removed,
centrifuged to remove debris, and stored at
80°C. The concentration
of virus particles was measured by an enzyme-linked immunosorbent assay
(ELISA) for the p30 capsid protein, as previously described
(9). Briefly, the wells of 96-well ELISA plates (Fisher
Scientific, Agawam, Mass.) were coated with 100 µl of a p30 antibody
(10 µg/ml) (purified from the supernatant harvested from the CRL-1912
hybridoma cell line [American Type Culture Collection, Rockville,
Md.]) per ml with overnight incubation at 4°C. The next day,
nonspecific binding sites were blocked with 200 µl of BLOTTO blocker
in Tris-buffered saline (Pierce, Rockford, Ill.) for 30 min at 37°C.
The samples containing the lacZ virus were thawed at 37°C
and boiled for 5 min to expose the capsid protein. The denatured
particles were then incubated (at 100 µl per well) for 1 h at
37°C. After washing with PBS-0.05% Tween 20, a secondary antibody,
goat polyclonal anti-p30 antibody (78S221; Quality Biotech, Camden,
N.J.), was added at a 1:300 dilution in BLOTTO (100 µl per well) for
1 h at 37°C. This was followed by washing with PBS-0.05% Tween
20 and incubation for 1 h at 37°C with 100 µl of a horseradish
peroxidase-conjugated rabbit anti-goat immunoglobulin G polyclonal
antibody (Zymed Laboratories, South San Francisco, Calif.) diluted
1:5,000 in BLOTTO. The substrate (10 mg of
o-phenylenediamine dihydrochloride and 10 µl of
H2O2 in 25 ml of substrate buffer containing
5.1 mg of citric acid mono-hydrate per ml and 13.78 mg of
Na2HPO4 · 7H2O per ml in
distilled water) was added (100 µl per well), and the reaction was
allowed to proceed for 10 min before the addition of 50 µl of 8 N
H2SO4 (stop solution) per well. The optical
density was read at 490 to 650 nm with an ELISA plate reader (ThermoMax
plate reader; Molecular Devices, Menlo Park, Calif.).
 |
RESULTS |
Adsorption of retrovirus particles is diffusion limited.
Valentine and Allison used the theory of Brownian motion to develop a
model for the adsorption of virus particles on flat surfaces
(24). In their model, the fraction of adsorbed viruses, fads, is given as a function of time,
t, the diffusion coefficient of virus particles is
D, and the depth of the virus-containing medium is
l. The fraction of adsorbed viruses is defined as the ratio
of the number of adsorbed viruses, N, to the total number of
virus particles in solution, which is the product of virus concentration, Cvo, times the volume of the
virus-containing medium, V. Mathematically, the fraction of
adsorbed viruses is as follows:
|
(1)
|
In order to analyze the validity of this model in a
retrovirus-target cell system, we measured the adsorption of retrovirus to fibroblasts with an ELISA for the p30 capsid protein.
Retrovirus-containing medium was incubated at 37°C in tissue culture
dishes with or without a confluent monolayer of NIH 3T3 cells. At
various times, aliquots were removed and assayed for levels of p30
(Fig. 1). Without cells, the amount of
p30 remained relatively constant for the duration of the experiment,
suggesting that nonspecific binding and degradation of p30 were
minimal. In the presence of cells, the fraction of retrovirus particles
that remained in solution, fsol, decreased with
time and reached almost 50% in 33 h. With nonlinear regression
analysis to fit equation 1 to the fraction of adsorbed data
(fads = 1
fsol), we estimated a diffusion coefficient (D) for retroviral particles. The best-fit value of
D was 1.74 × 10
8 cm2/s,
which is close to the diffusion coefficient of other similar-size retroviruses (2 × 10
8 cm2/s)
(21).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 1.
Kinetics of retrovirus adsorption. lacZ
retrovirus with Polybrene was added either to an empty plate (open
circles) or to a plate confluent with NIH 3T3 fibroblasts (solid
circles). Adsorption was monitored with an ELISA that measured the
amount of p30 remaining in the medium. The diffusion coefficient was
calculated by fitting the experimental data to the Valentine and
Allison equation (line) by nonlinear regression analysis. The best-fit
value, D = 1.74 × 10 8
cm2/s.
|
|
Retrovirus particles are intrinsically unstable.
Although
equation 1 fits well with the adsorption data, it is unable to predict
the number of active retrovirus particles that are adsorbed over time
because it does not take into account the instability of retrovirus
particles. Previous studies have shown that retroviruses lose activity
with time. For several retroviruses used for gene therapy applications,
the half-life has been calculated to be 5 to 8 h (7, 11, 12,
18). For other retroviruses, the half-life has been reported to
be 3 to 9 h (19). Each of these studies measured
half-life in undiluted stocks of virus that also contained conditioned
medium produced by the packaging cell line. To determine if decay was
intrinsic to the virus particle or was affected by the presence of
conditioned medium, we compared the stability at 37°C of undiluted
versus diluted lacZ virus (diluted 1:100 in fresh medium).
At various time points, aliquots were removed, further diluted in fresh
medium, and used to transduce NIH 3T3 cells. Undiluted and diluted
lacZ virus declined with nearly identical kinetics
(t1/2 = ~6.5 h) (Fig.
2), suggesting that decay is intrinsic to
the particles and is not influenced by conditioned medium.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
Recombinant retroviruses decay with a half-life of
~6.5 h in fresh and conditioned media. Undiluted (solid circles) or
diluted (1:100) lacZ retrovirus (open circles) was incubated
at 37°C. At various times, 0.5-ml aliquots were taken and frozen. To
test the activity of the virus, NIH 3T3 cells were plated at 6.0 × 104 cells per well in six-well plates and the next day
were transduced with 1.0 ml of lacZ retrovirus for 4.0 h at a final dilution of 1:500 in the presence of Polybrene. Two days
later, the number of gene transfer events (CFU) was measured by X-Gal
staining.
|
|
We modified equation 1 to account for decay, assuming decay is a
first-order reaction; thus the fraction of adsorbed retrovirus particles which are active, factive, is given as
|
(2)
|
The only difference is the term
, which is equal to the rate of
decay, kdv, divided by the rate of diffusion,
D/l2. With very long adsorption times, the
exponential term in equation 2 tends to be 0, and the fraction of
adsorbed active particles reaches a constant whose value is
1. If a
virus is stable and does not decay, then
= 0, equation 2 becomes identical to equation 1, and for very long times the fraction
of adsorbed particles asymptotically approaches a value of 1. If,
however, a virus decays, only a fraction of the virus particles will
then be active by the time they diffuse and adsorb on the cell surface.
At very long times, the fraction of adsorbed particles asymptotically approaches a value, <1, that depends on the rate of decay relative to
the rate of diffusion as expressed in the ratio
.
Decay limits the number of virus particles that have activity when
they adsorb.
To reveal the relationship between decay and the
adsorption of active particles, we simulated the adsorption of viruses
of differing decay rates or half-lives with equation 2 (Fig.
3). Adsorption to a confluent layer of
cells in a six-well plate with 1 ml (l, ~1.0 mm) of
virus-containing medium was simulated. At the start, the virus
concentration was 107 virus particles/ml and all virus
particles were active. As shown in Fig. 3, the number of adsorbed
particles that are active decreases as the half-life decreases.
Although all were active at the start, viruses with short half-lives
lose activity during the time it takes to diffuse to the cell surface.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Active and inactive particles adsorb, but virus decay
limits the number of adsorbed active particles. (A) Simulation of the
effect of various half-lives on the adsorption of active retrovirus
with equation 2. Confluent monolayers of cells in a six-well plate were
exposed for 48 h to 1.0 ml of retrovirus with an initial
concentration of 107 active particles per ml and different
half-lives. Both the rate of adsorption of active particles and the
steady-state levels decrease as half-life decreases. (B) Decay of virus
activity has minimal effect on virus adsorption. lacZ virus
was divided into two aliquots; one was decayed by incubation for
24 h at 37°C, and the other was an untreated control. (C) To
measure adsorption, NIH 3T3 cells (1.5 × 105 per well)
were plated in a six-well dish. After 72 h, the medium was
replaced with the control or with decayed virus sample containing 8 µg of Polybrene per ml. After 2 h, the virus was removed, the
cells were lysed, and the lysate was analyzed for the presence of p30
capsid protein via ELISA.
|
|
It also follows that if significant numbers of viruses are losing
activity, those viruses which do successfully infect a cell represent
only a fraction of the total number of active particles in the starting
stock. With the data from Fig. 3, we calculated the fraction of the
initial virus particle number that would have activity after a 24-h
adsorption. This fraction decreases with decreasing half-life (i.e.,
41%, t1/2 = 1,000 h; 39%,
t1/2 = 100 h; 23%,
t1/2 = 7 h; and 9%,
t1/2 = 1 h). Thus, for a typical retrovirus with a half-life of 7 h, this simulation shows that for every 5 particles that adsorb during the 24 h, at the most only ~1 will have activity when it adsorbs, even if all particles were active at the
start of transduction. Conversely, for each successful gene transfer
event there must be, at least, ~4 other virus particles that were
active in the initial stock at the start of the transduction assay.
Although decay limits the number of adsorbed particles that are active,
it was unclear whether active and inactive particles adsorb with the
same efficiency. To determine if decay influences adsorption, we thawed
a stock of virus and divided it into two aliquots. The control aliquot
was refrozen immediately, while the decay aliquot was refrozen after
incubation for 24 h at 37°C. The bioactivity of the decayed
stock was about 100 times lower than that of the control (Fig. 3B). We
then performed 2-h adsorption experiments on NIH 3T3 cells with these
same samples (Fig. 3C). The control and decayed stocks yielded
comparable levels of p30 adsorption, suggesting that the loss of virus
activity does not impair the adsorption of the particle.
Typical volumes of virus are in excess and do not limit the number
of virus particles that have activity when they adsorb.
Given the
limitations caused by diffusional resistances and decay, the depth of
the virus-containing medium should play a role in viral adsorption. We
used equation 2 to simulate the effects of various depths on the number
of adsorbed, active retrovirus particles. As shown in Fig.
4A, there is a critical
depth beyond which the number of adsorbed active particles remains
relatively unchanged. We define the critical depth as the depth at
which the number of adsorbed active particles reaches 95% of the
maximum (plateau) value. Since the distance that a particle travels
increases with time (l =
2Dt), the critical
depth increases with the time of adsorption (i.e., 0.16 mm,
tads = 2.5 h; 0.23 mm,
tads = 5 h; 0.33 mm,
tads = 10 h; 0.4 mm,
tads = 20 h; and 0.45 mm,
tads = 48 h) (Fig. 4B). The largest
critical value corresponds to the distance that a virus particle
travels within approximately two half-lives (in this simulation,
t1/2 = 7 h). Therefore, for volumes of 0.5 ml and larger (typically used in a six-well plate), adsorption of
active particles does not increase with increasing volume. Although an
increase in volume above 0.5 ml provides more total active particles,
the distance they must diffuse to reach the cell surface is also
increased. As a result, most of the additional particles lose activity
before they are adsorbed. For exceedingly small volumes, the situation
is different. At low volumes (<0.2 ml), the diffusional distance to
the target cells is short, and thus increasing volume does result in
the adsorption of more active particles. However, these small volumes
are rarely used. Typical transductions are not limited by the volume of
virus.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of various volumes on the adsorption of
active retrovirus. (A) Simulation of the effect of various volumes on
the adsorption of active retrovirus with equation 2. Confluent
monolayers of cells in a six-well plate were incubated for 48 h
with different volumes of retrovirus with an initial concentration of
107 active particles per ml (t1/2 = 7.0 h). This simulation shows that for volumes which are typically
used (0.5 and 1.0 ml), there is no significant difference in the number
of adsorbed active particles. Beyond a critical volume, there is no
significant increase in the number of adsorbed active particles.
Differences only occur for exceedingly small volumes that are rarely
used in six-well plates (0.2 and 0.1 ml). (B) Data from the same
simulation plotted as a function of liquid depth or volume for
different adsorption times to more accurately illustrate the threshold
volume. The critical volume varies for different adsorption times,
because the particles have additional time to diffuse greater
distances. (C) The number of infectious events does not increase for
volumes of retrovirus above the critical volume. NIH 3T3 cells
(8.0 × 104 cells/well; six-well plate) were
transduced for 2.5 h the next day with different volumes of
lacZ retrovirus diluted 1:500. Two days later, the number of
CFU was measured by X-Gal staining. Increasing the volume of retrovirus
fourfold from 0.5 to 2.0 ml did not increase the number of CFU, in
agreement with the predictions of the mathematical model. A decrease in
CFU occurred only with 0.25 ml of virus, a volume below the threshold
volume.
|
|
This simulation of varying volumes shows that error can be introduced
into the computation of titer. Titer (CFU/milliliter) is the number of
CFU times the dilution factor of the virus stock, divided by the volume
of virus used in the transduction assay. If the liquid depth of the
virus is above the critical value, CFU is not linearly dependent on
volume and error can be introduced into titer if CFU is normalized to
volume. For example, if 2.0 ml of virus-containing medium is used in a
six-well plate, then the titer may be underestimated by at least
fourfold, since the number of CFU should be the same when the volume is
between 0.5 and 2.0 ml.
To test this prediction, transduction experiments were performed with
different volumes of virus (0.25 to 2 ml), and the target cells were
exposed to the virus for 2.5 h (the same conditions as in our
simulation) to avoid evaporation of the medium. As shown in Fig. 4C,
the number of CFU was unchanged for volumes of 0.5 ml or greater, in
agreement with the prediction of equation 2 (Fig. 4A and B). A decrease
in the number of CFU only occurred with 0.25 ml, a volume of virus
below the critical volume.
The number of gene transfer events is proportional to cell
density.
An additional complexity in retrovirus-mediated gene
transfer is the fact that the target cells are never infected at
confluence. Rather, the cells are plated at subconfluent densities in
order to promote cell division, a requirement for successful retrovirus transduction (14). To test the relationship between cell
density and transduction, we transduced varying numbers of NIH 3T3
cells with a range of lacZ virus concentrations for 4 h
to minimize changes in cell density (Fig. 5). Not surprisingly, the
number of CFU is proportional to virus concentration, with less-diluted virus stocks producing more CFU with all cell densities tested (Fig.
5A). Figure 5B also shows that CFU is proportional to cell density. For
all virus concentrations, the number of CFU is larger when the cell
density is increased. The probability of a virus contacting a cell is
increased as the dish is covered with more cells. Linearity begins to
break down at the higher cell densities, presumably because
transduction is influenced by changes in the rate of cell division. In
a typical transduction assay, cell density is not standardized between
labs, and it is clear from Fig. 5 that cell density can significantly
alter the values of titer. There was a sixfold difference in the number
of CFU when the same virus concentration was assayed on 2 × 104 versus 14 × 104 cells.
Equations 1 and 2 are valid only when target cells cover the entire
surface of the dish, but standard transductions are performed on
subconfluent cultures. In this surface topography, viruses adsorb on
adsorbent patches (target cells) sparsely distributed on a nonadsorbent
surface, thereby requiring a different mathematical treatment to
describe the particle flux. Since the cell densities typically used in
transduction experiments are low, the distance between target cells is
on the order of a few cell diameters. In this case, it is reasonable to
assume that the diffusion of virus particles onto one cell does not
affect the diffusion onto a neighboring cell. We approximated this
problem as equivalent to the diffusion of virus particles onto the
surface of a disk-shaped target cell lying on a flat plate, a problem
previously solved for the flux of current at a stationary disk
electrode (22). Therefore, to derive an equation that
estimates the number of active virus particles,
Nactive, adsorbed on a dish of subconfluent cells, we modified the equation of Shoup and Szabo (22) to
account for virus decay as follows:
|
(3)
|
where AVC is the number of adsorbed active retroviral particles
per target cell, Nco is the total number of
cells at the start of transduction, ac is the
average radius of the target cells, D is the diffusion
coefficient of the virus, Cvo is the starting
concentration of active retrovirus particles, and S is the
number of active virus particles adsorbed on a cell relative to a
starting virus concentration. The function h(t) was derived by Shoup and Szabo and reflects the flux of particles on each cell at
time t, over the steady-state particle flux (22).
Since transduction is a multistep process (adsorption through gene
expression) and not all steps proceed with 100% efficiency, we
introduced the term
, the overall efficiency of
1. For NIH 3T3
cells that are known to have high transduction efficiency, we set
= 1.
From equation 3, it can be seen that most of the variables are easily
defined or controlled when setting up a transduction. For a range of
commonly used adsorption times and several target cell radii, we have
provided numerical values for the integral of equation 3 (Table
1). One term that needs to be measured is ac, the average radius of the target cells. To
compute the radius, we measured the area of 100 NIH 3T3 cells in 40 randomly chosen fields. The average area of a single cell was
152.7 ± 48.8 µm2, yielding an average radius of
approximately 7 µm. For short adsorption times (2 to 4 h), the
total area occupied by all cells remains approximately constant. The
other unknown term of equation 3 is Cvo, the
concentration of active retrovirus particles in the medium at the start
of transduction. This term can be calculated with equation 3, and then
the concentration of active retroviruses in the undiluted virus
stock is obtained by multiplying Cvo by the
dilution factor applied when setting up the assay to measure CFU.
Alternatively, Cvo can be calculated by dividing
the slope of the linear curves (CFU versus Nco)
by the function S (see equation 3).
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Numerical values of the integral in equation 3 for
various times of exposure of cells to the virus and target cell
radii, ac
|
|
Equation 3 predicts that the number of CFU is linearly proportional to
cell density. As shown in Fig. 5, this is
true over a range of cell densities, but it does not hold at very high
cell densities. Therefore, for each cell type, it is important to
determine the range of target cell numbers for which the number of CFU
is linear. With the slopes of all four curves in Fig. 5B, we determined Cvo as the ratio slope/S. The average
value of Cvo was (6.25 ± 0.85) × 105 active retroviral particles/ml when assayed on NIH 3T3
cells.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 5.
The number of gene transfer events is proportional to
the concentration of retrovirus and the number of target cells. NIH 3T3
cells were plated at various densities (1.0 × 104,
2.0 × 104, 4.0 × 104, and 8.0 × 104 cells/well; six-well plate) and were transduced the
next day (3.5 h) with 1.0 ml of lacZ retrovirus of different
dilutions (1:250, 1:500, 1:1,000, and 1:2,000) in the presence of
Polybrene. At the start of transduction, the number of target cells was
counted in parallel wells. Two days later, the number of CFU was
measured by X-Gal staining. The number of CFU is plotted as a function
of virus dilution (A). CFU increases as virus concentration increases.
The number of CFU is plotted as a function of cell number at the start
of transduction (B). The number of CFU increases as cell number
increases.
|
|
Cvo is not the same as titer. As shown in Fig.
5, values of titer would change sixfold, depending on how many cells
were used in the transduction assay. The same lacZ virus
stock has a titer of 8.3 × 103 CFU/ml when assayed on
the lowest cell number or 4.7 × 104 CFU/ml when
assayed on the highest cell number. In contrast to titer,
Cvo was independent of target cell number. Also
of interest is the fact that values of titer range from 1 to about 8%
of the concentration of active virus particles,
Cvo. This suggests that the initial
concentration of active retrovirus particles is much higher than the
number of particles that successfully produce a gene transfer event
(12).
RTE of target cells.
In equation 3, all postadsorption steps
are lumped into the term
; however, this factor may vary between
target cell types. To compare the transducibility of different cell
types, we used the same lacZ stock to transduce varying
numbers of either NIH 3T3 cells or diploid human fibroblasts. As shown
in Fig. 6, values of CFU were lower on
human fibroblasts than on NIH 3T3 cells, even though human fibroblasts
were slightly larger than NIH 3T3 cells, with an average surface area
of 285 µm2 and an average radius of 10 µm. In the range
of cell densities where the number of CFU is linearly proportional to
the number of target cells, we can write equation 3 for both cell types
and then divide by parts to obtain an expression for the ratio of efficiencies or the relative transduction efficiency (RTE), as a
function of the ratio of the number of gene transfer events and the
ratios of the number and radii of the target cells:
|
(4)
|
where I is the integral as shown in equation 3 (for
numerical values, see Table 1). Alternatively, the ratio of lumped
efficiencies can be written as a function of the slopes of the linear
curves (from equation 4):
|
(5)
|
The integral, I, is a weak function of the cell radius.
The ratio of the integrals may be significant only for short adsorption times (Table 1), but for longer times (e.g., 4 to 8 h), it is only
slightly greater than one and, therefore, it does not contribute significantly to the value of RTE. With equation 5 and the slopes of
the linear parts of the curves in Fig. 6, we calculated the lumped
efficiency of transduction of human fibroblasts to be 15% of the
efficiency of NIH 3T3 cells.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 6.
Values of CFU of the same retrovirus stock are different
on NIH 3T3 cells versus HuFb. Cells were plated at various densities
and were transduced the next day (3.5 h) with 1.0 ml of lacZ
retrovirus (diluted 1:250). At the start of transduction, the number of
target cells was counted in parallel wells. Two days later, the number
of CFU was measured by X-Gal staining. The number of CFU of the same
virus stock is lower on human fibroblasts; however, for both cell types
there is a range of cell densities where the number of CFU is linearly
proportional to cell number.
|
|
AVC: an alternative to MOI.
The MOI (the number of infectious
viruses per cell) is typically used to predict the extent to which a
cell population is transduced. However, since titer is used to compute
MOI, it suffers from the same lack of standardization and accuracy. As
an alternative, we propose AVC, the number of active retrovirus
particles that would adsorb per cell during a given adsorption time.
According to equation 3, the only variables needed to calculate AVC are Cvo and
. For example, if NIH 3T3 cells
(ac = 7 × 10
4cm)
(
= 1) are infected for 4 h with a viral stock with
106 active particles/ml (i.e.,
Cvo = 106 active particles/ml)
and the virus has a 7-h half-life, the expected number of adsorbed
active particles will be 0.6 particles/cell. Since the transduction
efficiency
is probably less than one (
1), the value of
AVC is an upper limit. For cell targets other than NIH 3T3 cells, this
analysis requires the measurement of RTE.
 |
DISCUSSION |
Although titer is a widely used quantitative measure of the
bioactivity of a stock of recombinant retrovirus, the key parameters of
the transduction assay used to compute titer have not been standardized. Titer is a measure of the number of retroviruses that
successfully transduce target cells under a very specific set of
conditions, and thus rigorous comparisons between experiments, laboratories, and clinical trials are difficult. Our data and other
published studies have shown significant problems with titer (15). In this study, we show that titer can vary (i) 6-fold, depending on the number of target cells; (ii) ~6- to 7-fold,
depending on the target cell type (NIH 3T3 cells versus human
fibroblasts); (iii) 3- to 4-fold, depending on the adsorption time (2 versus 24 h); and (iv) 4-fold, depending on the volume of virus
used in the transduction assay. In this paper, we present a
mathematical model with experimental support of how certain
physicochemical parameters of the transduction assay (time of
adsorption, volume of virus, target cell number, and target cell size),
as well as the intrinsic properties of virus particles themselves
(diffusion coefficient and half-life), influence the adsorption of
active viruses and the measurement of the activity of a virus stock. From these analyses, we have derived Cvo, the
starting concentration of active particles in a stock of retrovirus;
AVC (active viruses/cell), the predicted number of active particles
that would be adsorbed per cell in a given adsorption time; and RTE,
the relative transduction efficiency of one cell type versus another.
Since these expressions standardize the key parameters of the
transduction assay, they are more reliable than titer (and MOI) and
should aid in the quantitative comparison of data.
To compute Cvo from equation 3 requires input of
the time of adsorption, cell number, and cell radius as well as the
number of CFU from the transduction assay. To be accurate, the number of CFU must be linearly proportional to cell number and our data show
that this is true over a range of cell densities. However, this range
can vary between cell types; as cell numbers were increased beyond this
range, the number of CFU declined, possibly due to a decrease in the
rate of cell growth, which is known to influence transduction (2,
14). Equation 3 assumes that every particle that adsorbs on the
cell surface will result in a successful gene transfer event; however,
since the probability of each step after adsorption is
1 (parameter
in equation 3), values of Cvo are a lower
limit. Nevertheless, Cvo, the concentration of
active viruses at the start of transduction, is significantly higher than titer. This is explained by the fact that retrovirus-mediated gene
transfer is limited by the slow diffusivity and decay of the virus
particles, consistent with the conclusions of other investigators
(5, 6). In one study, transduction was improved by flowing
virus through a porous membrane with attached cells (6),
which suggested that the stock contains additional active particles if
they are brought to the target cells fast enough. In another study, the
same virus stock was used to transduce multiple dishes of target cells
in a series. The number of transduced cells changed only slightly with
each successive dish (23), which suggested that the number
of active viruses is greater than what can be determined by a single
measurement of titer. Our simulation data show that transduction is
independent of volume for liquid depths above 500 µm. Those viruses
located more than 500 µm above the cells do not contribute
appreciably to the number of gene transfer events, in agreement with
our previous report (15) and those of other investigators
(5, 6). Retroviral particles travel by diffusion
approximately 300 µm in one half-life (t1/2 = 7 h). Taken together, these results suggest that retroviral stocks
contain a significant fraction of particles that are active and could
transduce a cell if they reached the cell surface before they decay.
Since Cvo is higher than titer, this indicates
that a significantly larger fraction of virus particles in a stock are
active than has been previously thought. Based on measurements of
titer, it has been widely believed that only a very small fraction of the particles in a stock are active and the vast majority are inactive
defective particles. It has been estimated that between 0.1 and 1% of
the particles are active (20). In our study, we show that
the limitations of virus diffusion and decay prevent many of the active
virus particles in a stock from successfully transducing a cell. These
particles are not inherently defective at the start of infection but
rather lose activity before they can diffuse, adsorb, and successfully
transduce a cell. The values of Cvo that we
calculate in this paper are at least 10-fold higher than those of
titer, and thus stocks of virus have many more active particles than
previously thought. We do not assert that all particles are active in a
stock of retrovirus. During production of the virus by the packaging
cell line, virus decay does occur and defective particles do accumulate
in the stock. Based on the kinetics of production and decay, we
estimated in a previous study that, at most, ~38% of the particles
are active in a typical stock produced at 37°C over 24 h
(12). The remainder of the particles are truly defective
because they have decayed during the production process. In addition,
the proportion of defective particles may be somewhat higher due to the
possibility that some particles were defective at birth as a result of
errors in assembly. Strategies that improve gene transfer, such as
convective devices (6) and centrifugation (4), do
so because they deliver more active virus particles to the cell surface
in the shortest possible time. Good estimates of the true number of
active virus particles in a stock, as provided by
Cvo, can help determine the effectiveness of
these and similar strategies as well as provide an estimate to the
maximum possible benefit achievable with these approaches.
In addition to limitations due to slow diffusivity and decay, the
efficiency of the various steps following the adsorption of an active
virus (i.e., internalization, intracellular processing, integration,
etc.) is not known and may vary between cell types. Therefore, we
introduced the term
into equation 3 to cover these efficiencies. In
this paper, we assume that
= 1 for NIH 3T3 cells because this
cell type is highly infectable with recombinant retroviruses. However,
this efficiency is probably <1, and thus it is likely that an active
virus particle which diffuses and adsorbs on the cell surface may not
lead to a successful transduction event, because it may lose activity
at one of the many subsequent steps. Nevertheless, the particle was
active (not defective) in the starting virus stock and was active when
it adsorbed. If
< 1, then the proportion of active virus in a
virus stock is even higher than the estimates provided in this paper.
Thus, our estimates of Cvo, the concentration of
active virus in the starting stock, is a lower limit.
The fact that titer does not accurately reflect the true number of
active particles in a retrovirus stock has important implications for
in vivo gene transfer. The related lentivirus vectors are being used
for in vivo gene transfer, and the potency of these stocks is measured
as a titer (16). Since titer significantly underestimates
the number of active particles, it will be difficult to accurately
quantitate the true potency of these stocks after in vivo injection.
We used our analysis to calculate RTE, the relative transduction
efficiency of various cell types with respect to a standard cell type,
such as NIH 3T3 cells. Equation 5 shows that the transduction efficiency
the probability of successful gene transfer following virus
adsorption
is not just the simple ratio of the numbers of CFU on both
cell types; rather, it must also incorporate the number and radii of
each cell type. Comparison of the RTE of different cell types is
accurate only when CFU is linearly proportional to cell number. The RTE
of human fibroblasts, which have radii slightly larger than NIH 3T3
cells, was calculated to be 15% of the efficiency of NIH 3T3 cells,
suggesting that, at most, one of six active viral particles that adsorb
on human fibroblasts will lead to a successful gene transfer event.
Since the flux of particles to a cell with a larger radius should be
increased, the difference in RTE must be attributable to differences in
the efficiency of any of the numerous processes that lead to successful integration and transgene expression that we have lumped into the term
. For example, NIH 3T3 cells divide more rapidly (in ~12 h) than
human fibroblasts (~24 h) and since retroviruses decay after
internalization with a half-life of about 6 h (1, 3), the additional time through the cell cycle could be one explanation for
the decrease in transduction efficiency of human fibroblasts. Also,
differences in the transduction efficiency of cell types have been
attributed to differences in receptor number (17). By
normalizing the physical parameters of the transduction assay, measurements of RTE should help provide more accurate comparisons of
the transduction efficiencies of different cell types and aid biochemical investigations into the mechanisms of these differences.
We also computed AVC, the predicted number of active particles that
would be adsorbed per cell in a given adsorption time, and propose this
as an alternative to MOI. MOI, an expression based on titer, is often
used to determine the probability of infection of a population of
target cells by DNA and RNA viruses. However, recent experimental
results have shown that increasing the number of retrovirus particles
per target cell, either by increasing the volume of retrovirus solution
(references 5 and 15 and data in
this communication) or by decreasing the number of target cells
(10, 15), did not result in increased levels of
transduction, suggesting that MOI is not an appropriate measure of
retrovirus activity (15). Equation 3 shows that the average
number of active particles that adsorb on a target cell depends on the
time of adsorption, the concentration of virus (not the total number of
virus particles added), the radius of the target cell, the diffusion
coefficient, and the half-life of the virus. Because AVC describes the
number of active particles that adsorb per cell, it is useful for
predicting the extent to which a population of cells should be
genetically modified. If actual gene transfer efficiency is less than
AVC, this would indicate a problem with one or more steps in the gene
transfer process. For example, we recently reported that proteoglycans
secreted by the packaging cell line limit gene transfer at the highest doses of virus (13). This would be apparent as a significant deviation from AVC at high, but not at low, virus doses (because proteoglycan concentration is reduced by dilution). Likewise, AVC helps
to provide a measure of how well the transduction protocol is able to
effect gene transfer. The higher the values of AVC, the more effective
the transduction protocol. Because AVC is grounded in the physical
parameters of the transduction assay, it should be a more reliable
predictor of gene transfer than the currently used MOI.
 |
ACKNOWLEDGMENTS |
This work was supported in part by the NIH (HD-28528), NSF (BS
9800617), and the Shriners Hospital for Children.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Shriners
Hospital for Children, 51 Blossom St., Boston, MA 02114. Phone: (617)
371-4878. Fax: (617) 371-4950. E-mail: jmorgan{at}sbi.org.
Present address: Bioengineering Laboratory, Department of Chemical
Engineering, State University of New York at Buffalo, Amherst, NY 14260.
 |
REFERENCES |
| 1.
|
Andreadis, S.,
D. A. Brott,
A. O. Fuller, and B. O. Palsson.
1997.
Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half-life in the range of 5.5 to 7.5 hours.
J. Virol.
71:7541-7548[Abstract].
|
| 2.
|
Andreadis, S.,
A. O. Fuller, and B. O. Palsson.
1998.
Cell cycle dependence of retroviral transduction: an issue of overlapping time scales.
Biotechnol. Bioeng.
58:272-281[CrossRef][Medline].
|
| 3.
|
Andreadis, S., and B. O. Palsson.
1996.
Kinetics of retrovirus mediated gene transfer: the importance of the intracellular half-life of retroviruses.
J. Theor. Biol.
182:1-20[CrossRef][Medline].
|
| 4.
|
Bahnson, A. B.,
J. T. Dunigan,
B. E. Baysal,
T. Mohney,
R. W. Atchison,
M. T. Nimgaonkar,
E. D. Ball, and J. A. Barranger.
1995.
Centrifugal enhancement of retroviral mediated gene transfer.
J. Virol. Methods
54:131-143[CrossRef][Medline].
|
| 5.
|
Chuck, A. S.,
M. F. Clarke, and B. O. Palsson.
1996.
Retroviral infection is limited by Brownian motion.
Hum. Gene Ther.
7:1527-1534[Medline].
|
| 6.
|
Chuck, A. S., and B. O. Palsson.
1996.
Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titers.
Hum. Gene Ther.
7:743-750[Medline].
|
| 7.
|
Chuck, A. S., and B. O. Palsson.
1996.
Membrane adsorption characteristics determine the kinetics of flow-through transductions.
Biotechnol. Bioeng.
51:260-270[CrossRef].
|
| 8.
|
Crystal, R. G.
1995.
Transfer of genes to humans: early lessons and obstacles to success.
Science
270:404-410[Abstract/Free Full Text].
|
| 9.
|
Forestell, S. P.,
E. Bohnlein, and R. J. Rigg.
1995.
Retroviral end-point titer is not predictive of gene transfer efficiency: implications for vector production.
Gene Ther.
2:723-730[Medline].
|
| 10.
|
Kahn, M. L.,
S. W. Lee, and D. A. Dichek.
1992.
Optimization of retroviral vector-mediated gene transfer into endothelial cells in vitro.
Circ. Res.
71:1508-1517[Abstract/Free Full Text].
|
| 11.
|
Kotani, H.,
P. B. I. Newton,
S. Zhang,
Y. L. Chiang,
E. Otto,
L. Weaver,
R. M. Blaese,
W. F. Anderson, and G. J. McGarrity.
1994.
Improved methods of retroviral vector transduction and production for gene therapy.
Hum. Gene Ther.
5:19-28[Medline].
|
| 12.
|
LeDoux, J. M.,
H. E. Davis,
M. L. Yarmush, and J. R. Morgan.
1999.
Kinetics of retrovirus production and decay.
Biotechnol. Bioeng.
63:654-662[CrossRef][Medline].
|
| 13.
|
LeDoux, J. M.,
J. R. Morgan, and M. L. Yarmush.
1996.
Proteoglycans secreted by packaging cell lines inhibit retrovirus infection.
J. Virol.
70:6468-6473[Abstract].
|
| 14.
|
Miller, D. G.,
M. A. Adam, and A. D. Miller.
1990.
Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection.
Mol. Cell. Biol.
10:4239-4242[Abstract/Free Full Text].
|
| 15.
|
Morgan, J. R.,
J. M. LeDoux,
R. G. Snow,
R. G. Tompkins, and M. L. Yarmush.
1995.
Retrovirus infection: effect of time and target cell number.
J. Virol.
69:6994-7000[Abstract].
|
| 16.
|
Naldini, L.,
U. Blomer,
P. Gallay,
D. Ory,
R. Mulligan,
F. H. Gage,
I. M. Verma, and D. Trono.
1996.
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.
Science
272:263-267[Abstract].
|
| 17.
|
Orlic, D.,
L. J. Girard,
C. T. Jordan,
S. M. Anderson,
A. P. Cline, and D. M. Bodine.
1996.
The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction.
Proc. Natl. Acad. Sci. USA
93:11097-11102[Abstract/Free Full Text].
|
| 18.
|
Paul, R. W.,
D. Morris,
B. W. Hess,
J. Dunn, and R. W. Overell.
1993.
Increased viral titer through concentration of viral harvests from retroviral packaging cell lines.
Hum. Gene Ther.
4:609-615[Medline].
|
| 19.
|
Prince, A. M.
1960.
Quantitative studies on Rous sarcoma virus. V. An analysis of the mechanism of virulence of the Bryan "high titer" strain of RSV.
Virology
11:371-399[CrossRef][Medline].
|
| 20.
|
Rein, A. L.,
B. I. Gerwin,
R. H. Bassin,
L. Schwarm, and G. Schidlovsky.
1978.
A replication-defective variant of Moloney murine leukemia virus. I. Biological characterization.
J. Virol.
25:146-156[Abstract/Free Full Text].
|
| 21.
|
Salmeen, I.,
L. Rimai,
R. B. Luftig,
L. Liebes,
E. Retzer,
M. Rich, and J. J. McCormick.
1976.
Hydrodynamic diameters of murine mammary, Rous sarcoma, and feline leukemia RNA tumor viruses: studies by laser beat frequency light-scattering spectroscopy and electron microscopy.
J. Virol.
17:584-596[Abstract/Free Full Text].
|
| 22.
|
Shoup, D., and A. Szabo.
1982.
Chronoamperometric current at finite disk electrodes.
J. Electroanal. Chem.
140:237-245[CrossRef].
|
| 23.
|
Tavoloni, N.
1997.
A simple procedure to determine the biological titer of recombinant retroviral vectors.
Gene Ther.
4:150-155[CrossRef][Medline].
|
| 24.
|
Valentine, R. C., and A. C. Allison.
1959.
Virus particle adsorption. I. Theory of adsorption and experiments on the attachment of particles to non-biological surfaces.
Biochim. Biophys. Acta
34:10-23[Medline].
|
Journal of Virology, February 2000, p. 1258-1266, Vol. 74, No. 3
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lehmann-Che, J., Giron, M.-L., Delelis, O., Lochelt, M., Bittoun, P., Tobaly-Tapiero, J., de The, H., Saib, A.
(2005). Protease-Dependent Uncoating of a Complex Retrovirus. J. Virol.
79: 9244-9253
[Abstract]
[Full Text]
-
Petit, C., Giron, M.-L., Tobaly-Tapiero, J., Bittoun, P., Real, E., Jacob, Y., Tordo, N., de The, H., Saib, A.
(2003). Targeting of incoming retroviral Gag to the centrosome involves a direct interaction with the dynein light chain 8. J. Cell Sci.
116: 3433-3442
[Abstract]
[Full Text]
-
McDonald, D., Vodicka, M. A., Lucero, G., Svitkina, T. M., Borisy, G. G., Emerman, M., Hope, T. J.
(2002). Visualization of the intracellular behavior of HIV in living cells. J. Cell Biol.
159: 441-452
[Abstract]
[Full Text]
-
Kasman, L. M., Kasman, A., Westwater, C., Dolan, J., Schmidt, M. G., Norris, J. S.
(2002). Overcoming the Phage Replication Threshold: a Mathematical Model with Implications for Phage Therapy. J. Virol.
76: 5557-5564
[Abstract]
[Full Text]
-
O'Doherty, U., Swiggard, W. J., Malim, M. H.
(2000). Human Immunodeficiency Virus Type 1 Spinoculation Enhances Infection through Virus Binding. J. Virol.
74: 10074-10080
[Abstract]
[Full Text]